Ownership and insider activity for Xenon Pharmaceuticals Inc. (XENE): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy.
Price
| Price | $37.41 (closing price, October 30, 2026) |
| Market Cap | $3.6B |
| Exchange | NASDAQ |
| Country | CA |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-10-15 | Kelly Thomas Patrick | M-Exempt | 7,500 | |
| 2026-10-15 | Kelly Thomas Patrick | M-Exempt | 7,500 | |
| 2026-09-30 | Kelly Thomas Patrick | P-Purchase | 15,000 | $560K |
| 2026-09-30 | MORTIMER IAN | P-Purchase | 30,000 | $1.1M |
| 2026-09-01 | Svoronos Dawn | M-Exempt | 5,144 | $42K |
| 2026-09-01 | Svoronos Dawn | M-Exempt | 5,144 | $42K |
| 2026-08-28 | KENNEY CHRISTOPHER JOHN | S-Sale | 6,368 | $383K |
| 2026-08-28 | KENNEY CHRISTOPHER JOHN | S-Sale | 700 | $43K |
| 2026-08-11 | GANNON STEVEN | S-Sale | 10,000 | $641K |
| 2026-06-05 | PATOU GARY | S-Sale | 1,322 | $70K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $17.1M | $20.5M | $67.8M | $24.8M | $45.0M | $175.7M | $57.2M | $148.6M | $142.7M | $199.2M |
| Short-term Investments | $47.1M | $23.2M | $51.6M | $116.6M | $132.0M | $376.1M | $534.8M | $489.4M | $484.2M | $349.7M |
| Receivables | $200,000 | $438,000 | $151,000 | $813,000 | $1.8M | $2.8M | $986,000 | $874,000 | $1.5M | $1.4M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $65.7M | $44.8M | $121.4M | $144.9M | $181.8M | $559.0M | $600.3M | $645.0M | $635.3M | $560.6M |
| Property, Plant & Equipment | $1.4M | $1.1M | $991,000 | $2.6M | $6.9M | $12.5M | $16.9M | $18.8M | $18.2M | $15.3M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $67.5M | $46.1M | $122.4M | $147.7M | $189.2M | $572.0M | $754.1M | $964.8M | $798.1M | $981.7M |
| Accounts Payable | $1.5M | $1.3M | $665,000 | $2.5M | $3.0M | $3.8M | $8.5M | $8.6M | $5.1M | $3.9M |
| Short-term Debt | 0 | $700,000 | 0 | $4.7M | 0 | 0 | 0 | 0 | 0 | $1.5M |
| Total Current Liabilities | $3.5M | $4.1M | $4.1M | $43.4M | $14.8M | $14.3M | $22.7M | $27.3M | $35.6M | $41.8M |
| Long-term Debt | 0 | $6.1M | $15.0M | $10.9M | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $3.6M | $10.2M | $19.1M | $55.7M | $17.8M | $22.0M | $32.6M | $36.9M | $43.2M | $399.9M |
| Retained Earnings | -$142.7M | -$173.4M | -$207.9M | -$249.7M | -$278.5M | -$357.4M | -$482.7M | -$665.1M | -$899.5M | -$1.25B |
| Total Equity | $63.9M | $35.9M | $103.3M | $92.0M | $171.4M | $550.0M | $721.5M | $927.9M | $754.9M | $581.8M |
| Total Debt | 0 | $6.8M | $15.0M | $16.4M | $3.3M | $8.3M | $10.4M | $10.9M | $9.0M | $7.9M |
| Net Debt | -$64.1M | -$36.9M | -$104.3M | -$124.9M | -$173.7M | -$543.5M | -$581.7M | -$627.2M | -$617.9M | -$540.9M |
| Working Capital | $62.2M | $40.7M | $117.3M | $101.5M | $167.0M | $544.7M | $577.6M | $617.7M | $599.7M | $518.9M |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 21.02 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 2.94 |
Profitability
| Return on Equity | -43.98% |
| Return on Invested Capital | -35.10% |
| Return on Assets | -31.58% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: NBIX · JAZZ · AXSM · PRAX · ACAD · DNLI · SUPN
Explore sector: Healthcare · Biotechnology
More sections of XENE: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks